Cargando…
Single nucleotide polymorphisms of CD20 gene and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell lymphoma
BACKGROUND: R-CHOP has significantly improved survival rates of patients with diffuse large B cell lymphoma (DLBCL) by ~20% as compared to CHOP. CD20 antigen, highly expressed on more than 80% of B-cell lymphomas, is the target for rituximab. The goal of our study was to examine polymorphism in the...
Autores principales: | Ding, Huirong, Jin, Xuan, Ding, Ning, Fu, Zhiying, Song, Yuqin, Zhu, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686705/ https://www.ncbi.nlm.nih.gov/pubmed/23758737 http://dx.doi.org/10.1186/1475-2867-13-58 |
Ejemplares similares
-
EP300 single nucleotide polymorphism rs20551 correlates with prolonged overall survival in diffuse large B cell lymphoma patients treated with R-CHOP
por: Li, Jiao, et al.
Publicado: (2017) -
Homozygous A polymorphism of the complement C1qA(276) correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP
por: Jin, Xuan, et al.
Publicado: (2012) -
Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma
por: Fu, Zhiying, et al.
Publicado: (2014) -
Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab
por: Hu, Yunfei, et al.
Publicado: (2014) -
GM-CSF enhanced the effect of CHOP and R-CHOP on inhibiting diffuse large B-cell lymphoma progression via influencing the macrophage polarization
por: Zhang, Yu, et al.
Publicado: (2021)